Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Mindfulness-based cognitive therapy does not worsen depression symptoms

21

Aug 2026

Mindfulness-based cognitive therapy does not worsen depression symptoms

Researchers from the University of Wisconsin–Madison's Center for Healthy Minds (CHM), along with UW–Madison Department of Educational Psychology and a multi-university team, have found no evidence that mindfulness-based cognitive therapy (MBCT) increased a risk of symptom worsening, in a meta-analysis published in JAMA Network Open.

Lancet review examines possible amyloid-beta transmission through blood transfusions

21

Aug 2026

Lancet review examines possible amyloid-beta transmission through blood transfusions

A review and opinion piece published in The Lancet and led by UCL (University College London) and UCLH researchers discusses the possibility that blood transfusions may inadvertently transmit harmful brain proteins, and whether additional safety measures are warranted as a precaution whilst further research is conducted to better understand these potential risks.

Younger lung cancer patients show more targetable gene alterations

21

Aug 2026

Younger lung cancer patients show more targetable gene alterations

Younger adults with non-small cell lung cancer are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.

Scientists uncover safer way to tame cancer cell senescence

20

Aug 2026

Scientists uncover safer way to tame cancer cell senescence

Stopping tumor growth is only half the battle. Rather than kill tumor cells, many cancer therapies can only push them into cellular senescence, a state in which cells stop dividing but do not die. These "undead" cells will continue to release signals that reshape the tumor environment.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.